Upstream Bio

Contributing Author

Recent Articles by Upstream Bio

Sep-30	Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress UPB GlobeNewswire
Sep-09	Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum UPB GlobeNewswire
Sep-02	Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) UPB GlobeNewswire
Sep-01	Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) UPB GlobeNewswire
Aug-06	Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress UPB GlobeNewswire
Jul-08	Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) UPB GlobeNewswire
Jun-15	Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor UPB GlobeNewswire
Jun-05	Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 UPB GlobeNewswire
Jun-04	Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference UPB GlobeNewswire
May-20	Upstream Bio Appoints Stacy Price as Chief Technology Officer UPB GlobeNewswire
May-06	Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs UPB GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.